Option Care Health (NASDAQ:OPCH) Earns "Market Outperform" Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Option Care Health (NASDAQ:OPCH - Free Report) in a research report report published on Tuesday morning,Benzinga reports. JMP Securities currently has a $36.00 target price on the stock.

A number of other equities research analysts have also recently commented on OPCH. JPMorgan Chase & Co. lifted their target price on Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Barrington Research reiterated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research note on Monday, April 21st. Jefferies Financial Group upgraded shares of Option Care Health from a "hold" rating to a "buy" rating and raised their price target for the stock from $26.00 to $35.00 in a research note on Thursday, January 23rd. Finally, Bank of America upgraded Option Care Health from a "neutral" rating to a "buy" rating and upped their price objective for the company from $26.00 to $33.00 in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $33.75.

Option Care Health Stock Performance

Shares of OPCH traded up $0.72 on Tuesday, reaching $32.90. 1,560,649 shares of the company's stock traded hands, compared to its average volume of 1,776,860. The stock's 50 day simple moving average is $33.36 and its two-hundred day simple moving average is $28.76. The stock has a market cap of $5.40 billion, a PE ratio of 27.65, a PEG ratio of 2.30 and a beta of 1.07. Option Care Health has a 52-week low of $21.39 and a 52-week high of $35.53. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77.

Insider Activity at Option Care Health

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the transaction, the insider now owns 44,974 shares in the company, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.64% of the stock is owned by company insiders.

Institutional Investors Weigh In On Option Care Health

Institutional investors and hedge funds have recently modified their holdings of the company. Murphy & Mullick Capital Management Corp bought a new stake in Option Care Health during the 4th quarter worth approximately $26,000. UMB Bank n.a. increased its holdings in shares of Option Care Health by 41.7% in the fourth quarter. UMB Bank n.a. now owns 1,176 shares of the company's stock worth $27,000 after purchasing an additional 346 shares during the period. Signaturefd LLC raised its position in shares of Option Care Health by 487.9% in the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company's stock worth $28,000 after buying an additional 1,005 shares in the last quarter. Bessemer Group Inc. boosted its stake in Option Care Health by 62.3% during the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after buying an additional 599 shares during the period. Finally, Quadrant Capital Group LLC grew its position in Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock worth $40,000 after buying an additional 1,099 shares in the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.